Advancing our understanding of genetic risk factors and potential personalized strategies in pelvic organ prolapse: largest GWAS to date reveals 19 novel associated loci

Objectives: To identify the genetic determinants of pelvic organ prolapse (POP) and assess the predictive ability of polygenic risk scores (PRS) alone or in combination with clinical risk factors. Design: Meta-analysis of genome-wide association studies (GWAS) and PRS construction and validation. Setting: GWAS summary statistics from three European datasets and individual-level data from Estonian Biobank, including phenotype questionnaire and measurement panel, together with follow-up data from linkage with national health-related registries. Participants: A total of 28,086 women with POP and 546,321 controls of European ancestry. Genetic risk scores were derived from a dataset of 20,118 cases and 427,426 controls of European ancestry and validated in a target dataset of 7,896 cases and 118,895 controls. Cases were defined using ICD codes and classical risk factors were derived from questionnaire data and ICD10 codes. Results: The identified novel loci reinforce the role of connective tissue abnormalities, urogenital tract development and point towards association with a range of cardiometabolic traits. A novel PRS combining 3,242,959 variants demonstrated that women in the top 5 % have 1.63 (95% CI: 1.37 to 1.93) times the hazard of developing POP compared to the rest of the women. When analyzing PRS in incident disease, it showed similar predictive ability (Harrell C-statistic 0.583, sd=0.007) than five established clinical risk factors (number of children, body mass index (BMI), ever smoked, constipation and asthma) combined (Harrell C-statistic 0.588, sd=0.007) and demonstrated its incremental value in combination with these (Harrell C-statistic 0.630, sd=0.007). Conclusions: The largest GWAS meta-analysis in POP to date identified 26 genetic loci which establish links between POP and connective tissue abnormalities, urogenital development and cardiometabolic health. We present a PRS for POP which provides the first potential tool for preventive strategies and early detection of higher risk susceptibility to POP including genetic risk factors.


Introduction
Pelvic organ prolapse (POP) is characterized by a descent of pelvic organs into the vaginal cavity (1). It affects around 40% of women after menopause (2)(3)(4) and the lifetime risk of gynecological surgery for POP is up to 19% in the general female population (5). The main symptoms include a bothersome sense of vaginal bulge, urinary, bowel and/or sexual dysfunction, which substantially affects a woman's quality of life (6,7). The most common risk factors are age, number of offspring, operative vaginal delivery and BMI (8)(9)(10). However, despite its health and economic impact, the etiology of this complex disorder remains poorly understood and there is a lack of evidence for early detection of women who are at risk of developing POP.
POP is a multifactorial disorder and genetic factors have been estimated to explain 43% of the variation in POP risk in a twin study (11). A recent genome-wide association study (GWAS) of Icelandic and UK Biobank (UKBB) cohorts reported seven loci that associate with POP and point to a role of connective tissue metabolism and estrogen exposure in its etiology (12). Nevertheless, increasing the sample size is likely to boost the power for detection of more common risk variants, thus advancing our understanding of genetic risk factors underlying POP.
Polygenic risk scores (PRS), created based on GWAS results, can show the cumulative contribution of genetic factors towards disease risk. Therefore, PRS have been utilized as a tool to stratify individuals into different risk groups in complex diseases (13). However, PRS have never been used as a tool for predicting POP development. In contrast to physical examinations, which remain to be the goldstandard for POP assessment, PRS could serve as a tool to identify women with higher . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint genetic risk of POP and tailor individualized preventive strategies even decades before symptomatic POP appears.
Given this background, we present the largest GWAS in POP to date and further integrate it with additional data layers, such as gene expression, to propose potential causal genes in associated loci. Moreover, for the first time, we aim to construct and validate the predictive ability of PRS alone or in combination with classical risk factors, a tool that might favor preventive and personalized strategies in the future.

Study cohorts
Our analyses included a total of 28,086 women with POP and 546,321 controls of European ancestry from three different studies: summary level statistics from an Icelandic and UKBB GWAS meta-analysis (12)

GWAS meta-analysis
We conducted an inverse of variance weighted fixed-effects meta-analysis with single genomic control correction using GWAMA software (v2.2.2) (14). A total of 42,454,665 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint variants were included in the meta-analysis of 28,086 women with POP and 546,321 female controls. Genome-wide significance was set to p < 5 × 10 -8 . Assuming a prevalence of 5% for symptomatic POP and an overall POP prevalence of 40% in the population, total-h 2 was estimated by single-trait LD score regression using the metaanalysis summary statistics and HapMap 3 LD-scores (15,16) and converted to the liability scale.

Gene prioritization criteria
In order to move from genetic variants to plausible candidate genes, we used the following criteria. We first selected genes which showed evidence for regulatory effect of associated variants (based on gene expression or chromatin interaction data), implemented in FUMA platform v1.3.6a (17). Then, we prioritised candidate genes considering three main evidence levels: 1) distance from the association signal; 2) whether the lead signal is in high LD (r2>0.6) with a coding variant in any of the nearby genes; 3) whether the GWAS signal colocalises with a variant that affects gene expression; 4) finally, we utilized the Mouse Genome Database (18) (http://www.informatics.jax.org) to evaluate the effect of candidate genes in relevant mouse models.

Colocalization analyses
Colocalization analyses were conducted using COLOC (v. 3 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint signal. Prior probabilities were set to p1=1e-4, p2=1e-4 and p12=5e-6. Two signals were considered to colocalize if the posterior probability for a shared causal variant was 0.8 or higher.
In MAGMA v1.08, gene sets were obtained from Msigdb v7.0 for "Curated gene sets" and "GO terms". A total of 15,485 gene terms were queried. Tissue expression analysis was performed for 53 specific tissue types using MAGMA. DEPICT is an integrative tool that based on predicted gene functions highlights enriched pathways and identifies tissues/cell types where genes from associated loci are highly expressed.

Derivation of PRS for POP
In brief, PRS analysis requires two types of data: 1) base: summary statistics of genotype-phenotype associations at genetic variants genome-wide, and 2) target: genotypes and phenotype in individuals of an independent sample(29). We constructed a POP PRS based on the summary statistics of the meta-analyses including IceUK and FinnGen, with 20,118 cases and 427,426 controls of European ancestry, leaving out EstBB as an independent target dataset.
In short, each PRS was computed for each woman in the EstBB (N=126,791) by summing the product of the allele weighting and the allele dosage across the selected SNPs. We empirically evaluated a total of 19 different versions of PRS, implementing two different methodologies: PRSice2 (v2.3.3)(30) and LDPred(31), which use a clumping and thresholding and linkage-disequilibrium SNP-reweighting approach, respectively. Whilst PRSice2 automatically calculates and applies the PRS, in the case . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021.

Criteria for discovery and validation set definition
First, we divided the target dataset from EstBB into a discovery and validation dataset, according to their prevalent or incident status. The discovery dataset included 5,379 prevalent cases and 21,516 controls (4 controls per case). Since controls were defined as women who did not develop pelvic organ prolapse during follow-up, they tended to be younger than prevalent cases. In the discovery set, we tested all 19

Selection of best PRS model
The discovery set was used in the initial analyses in order to select the best predicting PRS version through a logistic regression model adjusted for age, age squared, first 10 principal components and batch effects. The model that offered the smallest pvalue towards case -control discrimination was selected for further analyses.
Predictive ability of PRS and classical risk factors . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint We standardised the best PRS version and also categorized it into different percentiles (<5%, 5%-15%, 15%-25%, 25%-50%, 50%-75%, 75%-85%, 85%-95%, >95%). Cox proportional hazard models were used to estimate the Hazard Ratios (HR) corresponding to one standard deviation (SD) of the continuous PRS for the validation dataset. Harrell's C-statistic was used to characterize the discriminative ability of each PRS. Cumulative incidence estimates were computed using Kaplan-Meier method.
While comparing different PRS groups with each other, age was used as a timescale to properly account for left-truncation in the data.
Next, we use the validation subset to assess the predictive ability of PRS and five clinical risk factors (number of children, BMI, ever smoked, asthma and constipation) alone or in combination, and clinical risk factors together with PRS. Information on the number of children, BMI and smoking were extracted from questionnaire data, whereas ICD10 codes J45 and K59.0 were used for asthma and constipation, respectively. Table 1 and Figure 1, 26 loci, with 30 independently significant lead signals, were associated with POP after meta-analysis. From these, 19 loci were novel findings and seven were reported previously (12). All lead variants were present in at least two out of the three datasets analyzed and were common variants (EAF>0.05) except for one replicated (EAF=0.01, rs72624976, p=1.14 × 10 -9 ) and one novel association (rs72839768, EAF=0.02, p=4.66 × 10 -9 ). The effect sizes of the lead variants were modest (odds ratios ranging from 0.84 to 1.19), which is consistent with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

As shown in
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint GWAS findings for other complex diseases (32). There was no evidence of excessive genomic inflation (λ=1.054) in the GWAS meta-analysis, suggesting minimal bias due to population stratification, genotyping artefacts, and/or cryptic family relationships ( Figure 2). SNP heritability in the meta-analysis was estimated to be 9.4% and 17.3%, considering POP prevalence of 5% (symptomatic) and 40% (overall), respectively. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Biological mechanisms underlying associated loci
Gene prioritisation was mainly weighted by evidence supporting either distance from gene transcription start site to association peak, eQTL colocalization analyses (posterior probability for a shared causal variant PP4>0.8) and/or genes containing exonic variation (Figure 2).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint Figure 2. Evidence for pelvic organ prolapse GWAS meta-analysis candidate gene mapping. Genes which showed evidence for regulatory effect of associated variants (based on gene expression, which correspond to all genes listed in the figure, or also chromatin interaction data shown as yellow dots) were selected. Then, we prioritised candidate genes considering three main evidence levels: A) genes near to the association peak were prioritised (green dots indicate the genes with transcription . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint start site (TSS) <100kb of the lead signal); B) genes containing coding variants or in high LD (r2>0.6) with these (shown as orange dots); C) genes containing shared causal variants between genetic variants and gene expression signatures unraveled by colocalization analyses (shown as pink dots); and D) genes which affected relevant phenotypes in mouse models (shown as blue dots).
Significant colocalization signals allowed us to prioritise EFEMP1, LDAH, VCL, Analysis of gene set and tissue/cell-type enrichment . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Genetic correlation
Pairwise genetic correlation with POP was estimated for 561 phenotypes using LD score regression implemented in LD-Hub (15,27 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint cardiometabolic, ICD10 diagnoses, job type, reproductive traits and self-reported conditions. Center values show the estimated genetic correlation (rg), which is presented as a dot and error bars indicate 95% confidence limits.

Phenome-wide associations
The phenome-wide association look-up of associated variants underlined several traits spanning abnormality of connective tissue, body measurements, cancer, cardiovascular disease, digestive system disorders, pulmonary function, reproductive health, liver disease, psychiatric disorders and other traits (Supplementary Figure 3 and 4, Supplementary Table 5 and 6).

PRS analysis
We found that the best performing PRS consisted of 3,242,959 SNPs and was built by LDPred. This version showed an OR=1.42 (1.37 to 1.47) and p=2.59 × 10 −89 towards the case-control discrimination in the discovery set (Supplementary Figure 5 and Supplementary Table 7).

Predictive ability of PRS and clinical risk factors
Analyzing the best PRS with the incident POP (N=2,517 cases, 96,139 controls), a continuous PRS distribution showed the highest Harrell's C-statistic (C-stat) of 0.616 (sd=0.006). In the validation set we observed a risk gradient within percentiles ( Figure   4). Women in the top 5% of the PRS distribution had 1.63 (95% CI: 1.37 to 1.93) times the hazard of developing POP compared to the rest of the women and 1.57 (95% CI: 1.29 to 1.91) times the hazard compared to women from the average (40-60%).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint However, it is important to note that this is a Kaplan-Meier estimate, which does not take into account competing risks such as death before developing the disease, and thus incidence rates might be overestimated.
In the validation subset of 2,104 cases and 24,780 controls who had clinical covariate data (Supplementary Table 8 Table   9).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Statement of principal findings
This study provides the most comprehensive analysis of genetic risk factors of POP to date, revealing many additional risk loci. We defined 26 genetic loci and used a combination of different data layers to map potential candidate genes, which provide

Interpretation of findings and comparison to other studies
Among the genome-wide significant loci, this study supports the role of one previous Subsequently, diverse mouse and human studies have reiterated its involvement with prolapse (34)(35)(36)(37). Additionally, we further propose several candidate genes (EFEMP1, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint CHRDL2, ACADVL, PLA2G6) which reinforce the role of connective tissue molecular changes as a key process in the pathogenesis of POP (38,39). For example, EFEMP1 encodes a fibulin and has been involved in alterations of connective tissue function as seen in inguinal hernia, pelvic organ prolapse and mouse studies (12,(40)(41)(42) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint Additionally, WT1, another proposed candidate gene, is a transcription factor involved in urogenital system development. Recently, a single-cell transcriptome profiling study of severe anterior vaginal prolapse described activity of WT1 in fibroblasts, and genes regulated by WT1 were enriched in terms related to actin filament behavior(52).
Moreover, WT1 has also been involved in cardiac development and disease(53-55), a link that was further supported by our phenome-wide association look-up results, since this region was associated with hypertension and cardiovascular disease Epidemiologic studies that investigate the association between cardiovascular risk factors and female pelvic organ prolapse are currently sparse. To date, two studies reported significant associations between metabolic syndrome parameters such as elevated triglycerides or reduced HDL-cholesterol and severity of POP (66,67).
Additionally, a prospective cross-sectional study that included a total of 984 middleaged Korean women showed that metabolic syndrome was significantly associated with the pelvic floor dysfunction, including pelvic organ prolapse (68). Although a few animal experiments hypothesized that microvessel damage or chronic ischemia of the pelvic floor may compromise pelvic floor function by affecting muscle tone or innervations(69-72) the role of vascular risk factors in pelvic organ prolapse remains to be characterized and further research is warranted.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint Beyond unraveling shared genetic architecture with connective tissue biology, reproductive and cardiovascular traits, genetic correlation analyses supported 'ever had hysterectomy' as the largest positive correlated trait with POP (rg=0.59, p=3.43 × 10 −17 ). This evidence might be worth considering for obstetrician-gynecologists when hysterectomy is indicated for benign causes, although an assessment of separate groups with defined causes of hysterectomy would be needed to better interpret the direction of this association.
Additionally, genetic correlation analyses highlighted a positive correlation with job types involving walking and/or standing and heavy physical work, which might have potential value to address counselling to women with higher risk to develop POP.

Genetic risk scores
To the best of our knowledge, this study presents the first genetic risk score model for POP, which showed similar predictive ability to several risk factors and demonstrated its added value in combination with established risk factors, in line with recent evidence for other complex diseases (73). Whilst in EstBB age was substantially increased in cases (mean=58.76,sd=12.01), than controls (mean=43.86,sd=16.06), predictive ability analyses in the validation set properly accounted for age by including it as the time scale, thus comparing only women from same ages and avoiding inflation in prediction solely due to age difference between cases and controls.
The present study also assesses the predictive ability of several clinical risk factors, showing that number of children is the most predictive clinical factor. This is in line with multiple evidence which describes parity as one of the strongest risk factors for POP (9), also mirrored by a positive genetic correlation between POP and number of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint children observed in this study. Constipation also had high predictive value for POP, in line with a study which observed a higher risk for constipation and lower fiber intake in women with prolapse compared to controls (74). Furthermore, our study supported smoking status as a good predictor for POP. However, there is no consensus in literature between this relationship (4,(75)(76)(77)(78). Additionally, we reinforce the relationship between BMI and pelvic organ prolapse (2,9,79). Whilst some evidence linked POP severity and bronchial asthma(80), our study concludes asthma is a poor predictor, in line with recent research which suggested that asthma is not a risk factor for POP (81). Nevertheless, these observations do not rule out the possibility that these links are established after developing POP, for instance constipation has been observed in the clinic to be both a cause and a consequence of POP, and similarly other comorbidities might appear as consequences of POP development. From a clinical point of view, we suggest that modifiable risk factors such as weight reduction and preventing constipation, along with Kegel exercises for pelvic floor muscle strengthening and avoiding heavy lifting, could be considered as preventive strategies for women with higher genetic risk to develop POP.
Recently, a validated screening tool (UR-CHOICE PFD Risk Calculator) was developed to identify pregnant women who are at higher risk for POP or other pelvic floor disorders (http://riskcalc.org/UR_CHOICE/) at 12 and 20 years after delivery (82).
Models were able to discriminate between women who experienced bothersome symptoms or received treatment at 12 and 20 years, respectively, for pelvic organ prolapse (concordance indices, 0.570, 0.627). However, this risk algorithm was designed for pregnant women, thus restricting its applicability only to a narrower group of women. Contrarily, genetic risk is stable, and thus evaluable throughout the lifespan.
Although the limited number of incident cases hinders assessing a predictive risk . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint algorithm including genetic and clinical risk factors, our study demonstrates the discriminative ability of five established risk factors and clearly demonstrates the potential and incremental value of PRS when added to a clinical combined model.

Strengths and weaknesses of the study
This study presents the largest GWAS for POP, which resulted in almost a 4-fold increase in the number of loci associated with POP. One of the strengths of this study is individual level data access in EstBB, containing genetic data of around 20% of Estonian adult population including phenotype questionnaire and measurement panel, together with follow-up data from linkage with national health-related registries, which facilitated the validation of PRS and the inclusion of clinical risk factors into a joint model.
The same biobank setting limits some aspects of the study. For instance, this study included women with POP identified using specific ICD codes, which hinders analyses considering different disease stages and severity. In the same line, the biobank setting limits the possibility to assess more extensive reproductive history information such as mode of delivery or newborn anthropometric measurements.
In regard to genetic correlation analyses, it is important to note that an observed association may not lead to inferring causality and many traits which showed a positive genetic correlation with POP are likely traditional lifestyle traits that share a strong genetic correlation without a direct causal relationship. Future research should also aim to infer causal relationships between the phenotypes uncovered by genetic correlation analyses, through Mendelian randomization principles.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint Overall, this GWAS meta-analysis and PRS construction focused on European ancestry populations, which challenges the generalizability of GWAS findings to non-European populations and warrants caution when extrapolating these results to other populations.

Unanswered questions and future research
Although gene expression data was a valuable tool for mapping potential candidate genes, future larger sample size in gene expression panels might add greater power to detect more significant associations and improve disentangling tissue specific signals in eQTL datasets (19). Whilst recent evidence suggests distance to the association peak as a good predictor for a causal gene (83,84), it is important to note that complex LD patterns between association signals might eclipse more distant genes which are the true causal ones. Overall, further functional follow-up is needed to better characterize the regulatory functions of the loci uncovered and experimental work is warranted to confirm and strengthen the role of the candidate genes we propose in the identified loci. Similarly, the role of rare variants into pelvic organ prolapse remains understudied and deserves further attention (85).
Whilst our study provides the first evidence to characterize the predictive ability of a POP PRS, future cohorts with longer follow-up time and an increased number of incident POP cases would enable more precise effect estimation and assess its translational potential to the clinic. Moreover, it remains to be determined how accurate these scores are across the lifespan; whereas genetic factors are stable, lifestyle factors and thus risk susceptibility might vary throughout time. Additionally, new PRS derived from other POP GWASs would be needed in order to assess the variability in genetic risk categorization for the same target individuals, as previous evidence . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint showed there is considerable variability between different PRS when assessing the same complex trait (86). Our joint model shows the best predictive ability to identify women in the general population who have high risk of pelvic organ prolapse and open up novel perspectives to change screening management in the future. Whilst these are exciting opportunities, novel clinical communication and infrastructures are required in order to ethically assess the information derived from prediction models combining genetic and clinical risk data, transforming its potential usefulness into an actual benefit for women with pelvic organ prolapse.

Data availability
Full meta-analysis summary statistics will be made available upon publication.

Declaration of Interests
The authors declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 10, 2021. ; https://doi.org/10.1101/2021.07.08.21260068 doi: medRxiv preprint